The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Treatment using mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in FL and MZL
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses findings from a trial on response-adapted treatment using mosunetuzumab, with or without obinutuzumab and polatuzumab vedotin, in treatment-naive follicular lymphoma (FL) and marginal zone lymphoma (MZL). To date, 38 patients have enrolled, showing a safety profile consistent with data from relapsed patients, with neutropenia being the most common grade 3/4 adverse event (AE). The trial reported an 81% complete response (CR) rate and a 71% measurable residual disease (MRD) rate. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen, Rapt, Merck, Janssen; Consultancy/Honoraria: SeaGen, Foresight Diagnostics, Abbvie, Janssen, Merck.
